Finoriq research workspace
Propanc Biopharma, Inc. (PPCB) Historical Metrics
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the. Review PPCB fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
- Company
- Propanc Biopharma, Inc. (PPCB)
- Ticker
- PPCB
- Market Cap
- $3.2M
- Latest Price
- $1.39
- Industry
- Biotech & Pharma
Propanc Biopharma, Inc. (PPCB) Current Valuation Metrics
Static valuation preview for Propanc Biopharma, Inc. (PPCB). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -454.6% | Net Income | TTM Q3 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -101.7% | Operating Cash Flow | TTM Q3 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 0.41x | Stockholders' Equity | Q3 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.